Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 5/2021

01-11-2021 | Endometrial Cancer | Original Article

MicroRNA-21 expression in cancer cells is an independent biomarker of progression-free survival of endometrioid endometrial carcinoma

Authors: Kimiya Sato, Morikazu Miyamoto, Masashi Takano, Hitoshi Tsuda

Published in: Virchows Archiv | Issue 5/2021

Login to get access

Abstract

Endometrial carcinoma is one of the most common gynecological cancers. MicroRNA-21 (miR-21) is the most consistently overexpressed miRNA in almost all human cancer types, and it might be a useful clinical biomarker and therapeutic target. However, its precise localization and significance in endometrial carcinoma have not been clarified. This study aimed to examine miR-21 expression in endometrial carcinoma and reveal its clinicopathological importance. We investigated miR-21 expression by in situ hybridization (ISH) using locked nucleic acid (LNA)-modified probes in 230 endometrial carcinoma patients. We evaluated miR-21 expression in cancer cells and stroma separately. High miR-21 expression in cancer cells was significantly associated with higher histological grade and lymph node metastasis. In Kaplan–Meier analysis, high miR-21 expression in cancer cells was significantly associated with poor progression-free survival. In particular, in endometrioid carcinoma, high miR-21 expression in cancer cells was an independent prognostic factor associated with poor progression-free survival, as well as older age and higher International Federation of Gynecology and Obstetrics (FIGO) stage.
Literature
1.
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRef
2.
WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours (WHO Classification of Tumours). IARC Press, Lyon
3.
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17CrossRef
4.
Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714CrossRef
5.
Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A et al (2020) The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 20:409–420CrossRef
6.
Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW (2013) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111:71–81CrossRef
7.
Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M (2008) MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12:2171–2176CrossRef
8.
Yamamichi N, Shimomura R, Inada K et al (2009) Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 15:4009–4016CrossRef
9.
Rask L, Balslev E, Jorgensen S et al (2011) High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS 119:663–673CrossRef
10.
Wang Y, Li J, Tong L et al (2013) The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. Jpn J Clin Oncol 43:813–820CrossRef
11.
Wang Y, Zhou S, Fan K, Jiang C (2019) MicroRNA-21 and its impact on signaling pathways in cervical cancer. Oncol Lett 17:3066–3070PubMedPubMedCentral
12.
Qin X, Yan L, Zhao X, Li C, Fu Y (2012) microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett 4:1290–1296CrossRef
13.
Zhao W, Geng P, Li Y, Wei X, Cheng J (2017) MicroRNA-21 promotes endometrial carcinoma proliferation and invasion by targeting PTEN. Int J Clin Exp Pathol 10:11489–11495PubMedPubMedCentral
14.
Gao Y, Dai M, Liu H et al (2016) Diagnostic value of circulating miR-21: an update meta-analysis in various cancers and validation in endometrial cancer. Oncotarget 7:68894–68908CrossRef
15.
Wang C, Li Q, He Y (2020) MicroRNA-21-5p promotes epithelial to mesenchymal transition by targeting SRY-box 17 in endometrial cancer. Oncol Rep 43:1897–1905PubMedPubMedCentral
16.
Eriksen AH, Andersen RF, Nielsen BS et al (2016) Intratumoral heterogeneity of microRNA expression in rectal cancer. PLoS One 11:e0156919CrossRef
17.
Zedan AH, Blavnsfeldt SG, Hansen TF et al (2017) Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations. PLoS One 12:e0179113CrossRef
18.
Chen C, Ridzon DA, Broomer AJ et al (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179CrossRef
19.
Cao Z, Yoon JH, Nam SW, Lee JY, Park WS (2012) PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J Cancer Res Clin Oncol 138:611–619CrossRef
20.
Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14:844–852CrossRef
21.
Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363PubMed
22.
McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 22:276–282CrossRef
23.
Kadera BE, Li L, Toste PA et al (2013) MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 8:e71978CrossRef
24.
Uozaki H, Morita S, Kumagai A et al (2014) Stromal miR-21 is more important than miR-21 of tumour cells for the progression of gastric cancer. Histopathology 65:775–783CrossRef
Metadata
Title
MicroRNA-21 expression in cancer cells is an independent biomarker of progression-free survival of endometrioid endometrial carcinoma
Authors
Kimiya Sato
Morikazu Miyamoto
Masashi Takano
Hitoshi Tsuda
Publication date
01-11-2021
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 5/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-021-03171-w

Other articles of this Issue 5/2021

Virchows Archiv 5/2021 Go to the issue

Original Article

Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping

Original Article

Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors

Brief Report

A systemic apolipoprotein A-IV-associated amyloidosis confirmed by proteome analysis

Original Article

Pyk2 level is a novel prognostic marker for patients with esophageal squamous cell carcinoma after radical surgery

Brief Report

The gastric disease of Napoleon Bonaparte: brief report for the bicentenary of Napoleon’s death on St. Helena in 1821

Original Article

Modifying phrases in surgical pathology reports: introduction of Standardized Scheme of Reporting Certainty in Pathology Reports (SSRC-Path)